Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy - PubMed
5 hours ago
- #personalized-therapy
- #gut-microbiome
- #antimetabolite-drugs
- Antimetabolite drugs are crucial for treating cancers and autoimmune diseases but face limitations due to systemic toxicity from gut microbiota dysbiosis.
- Gut microbiota significantly influences antimetabolite treatment outcomes, with complex bidirectional interactions between drugs and microbial communities.
- Common antimetabolites like 5-fluorouracil, methotrexate, and gemcitabine impact gut microbial communities, affecting treatment efficacy and toxicity.
- A framework for assessing chemotherapy-microbiota interactions includes pharmacokinetics, endogenous metabolite production, immune modulation, and apoptotic pathway modulation.
- Potential microbial biomarkers could predict treatment responses, and gut microbiota manipulation may enhance therapeutic efficacy.
- Advanced methodologies like metagenomics and real-time microbial monitoring are essential for understanding and optimizing antimetabolite drug use.